Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy

Blood

Volumn 91, Issue 5, 1998, Pages 1706-1715

  Lode, Holger N ^b   Xiang, Rong ^b   Dreier, Torsten ^b   Varki, Nissi M ^b   Gillies, Stephen D ^b   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BONE MARROW CELL; BONE METASTASIS; EFFECTOR CELL; GENE TARGETING; IMMUNE RESPONSE; IMMUNOMODULATION; KILLER CELL; LEUKOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROBLAST;

EID: 0032031429     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.5.1706     Document Type: Article

References (45)

1. Niethammer D, Handgretinger R: Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 31A:568, 1995
2. 2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261, 1995
3. 2 antibody 14.G2a. Cancer Immunol Immunother 35:199, 1992
4. 2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228, 1994
5. 2 mAb 14G2a in a phase I trial in pediatrie cancer patients. Cancer Immunol Immunother 41:29, 1995
6. Riethmueller G, Schneider-Gaedicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichelmayr R, Buggisch P. Witte J: Randomised trial of monoclonal antibody for adjuvant therapy of resected DukesC colorectal carcinoma (The German Cancer Aid 17-1A Study group). Lancet 94:1177, 1994
7. 3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 83:7893, 1986
8. Shiloni E, Eisenthal A, Sachs D, Rosenberg SA: Antibodydependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138: 1992, 1987
9. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823, 1982
10. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157:884, 1983
11. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 50:5234, 1990
12. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159, 1994
13. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474, 1989
14. Favrot MC, Floret D, Negrier S, Cochat P, Bouffet E, Zhou DC, Franks CR, Bijman T, Brunat-Mentigny M, Philip I, Philip T: Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4:499, 1989
15. 2 antibody 14.G2a plus IL-2 in children with refractory neuroblastoma: A report of the children's cancer group. Cancer 80:317, 1997
16. Roth JA, Cristiano RJ: Gene therapy for cancer: What have we done and where are we going. J Natl Cancer Inst 89:21, 1997
17. Schwinghammer TL, Bloom EJ: Pharmacologie prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation [review]. Clinical Pharmacy 12:736, 1993
18. Parkman R: Is chronic graft versus host disease an autoimmune disease? [review]. Curr Opin Immunol 5:800, 1993
19. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma métastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91:9626, 1994
20. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA: T-cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361, 1996
21. Becker JC, Varki NM, Gillies SD, Furukawa K, Reisfeld RA: An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Nat Acad Sci USA 93:7826, 1996
22. Becker JC, Varki NM, Gillies SD, Furukawa K, Reisfeld RA: Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98:2801, 1997
23. Koehne G, Zeller W, Stockschlaeder M, Zander AR: Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:149, 1997
24. Greene LA, Shain W, Chalazonitis A, Breakfield X, Minna J, Coon HG, Nirenberg M: Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. Proc Natl Acad Sci USA 72:4923, 1975
25. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA: Targeted interleukin-2 therapy of spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89:1586, 1997
26. Gillies SD, Lo KM, Wesolowski J: High-level expression of chimeric antibodies using adapted cDNA variable region casettes. J Immunol Methods 125:191, 1989
27. Gillies SD, Reilly EB, Lo KM, Reisfeld RA: Antibody-targeted interleukin 2 stimulates T cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428, 1992
28. 2 interleukin-2 fusion protein (ch14.18-IL-2). Clin Cancer Res 2:1951, 1996
29. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look AT, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466, 1993
30. Burchill SA, Bradbury FM, Selby P, Lewis IJ: Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer 31A:553, 1995
31. Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, Kato K: Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 77:1214, 1996
32. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K: Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 75:2757, 1995
33. Burchill SA, Bradbury FM, Smith B, Lewis IJ, Selby P: Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer 57:671, 1994
34. Raulet DH, Held W: Natural killer cell receptors: The offs and ons of NK cell recognition. Cell 82:697, 1995
35. Raulet DH: Recognition events that inhibit and activate natural killer cells. Curr Opin Immunol 8:372, 1996
36. Massague J: The TGF-beta family of growth and differentiation factors. Cell 49:437, 1987
37. Roszman T, Elliott L, Brooks W: Modulation of T cell function by gliomas. Immunol Today 12:370, 1991
38. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G: Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36:409, 1993
39. Schwartz RH: Models of T cell anergy: Is there a common molecular mechanism? J Exp Med 184:1, 1996
40. Smith KA: Lowest dose interleukin-2 immunotherapy. Blood 81:1414, 1993
41. Tigges MA, Casey LS, Koshland ME: Mechanism of interleukin-2 signaling: Mediation of different outcomes by a single receptor and transduction pathway. Science 243:781, 1989
42. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, Narula S, Caligiuri MA: The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 85:3577, 1995
43. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ, King I: Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184:579, 1996
44. Murphy C, Nikodem D, Howcroft K, Weissman JD, Singer DS: Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line. J Biol Chem 271:30992, 1996
45. van't Veer LJ, Beijersbergen RL, Bernards R: N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J 12:195, 1993